# IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

Study · id `cardio:ct-nct06139328` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06139328](<https://clinicaltrials.gov/study/NCT06139328>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06139328

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 160 participants.

## Technical summary

Registry record NCT06139328. Randomized; triple masking; primary purpose treatment. Start 2023-12-05 (actual); primary completion 2025-09-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT06139328, source copy `cardio:ctgov-nct06139328-2026-07-27`, retrieved 2026-10-26)
- Started: 2023-12-05 (actual) (ClinicalTrials.gov record NCT06139328, source copy `cardio:ctgov-nct06139328-2026-07-27`, retrieved 2026-10-26)
- Primary completion: 2025-09-02 (actual) (ClinicalTrials.gov record NCT06139328, source copy `cardio:ctgov-nct06139328-2026-07-27`, retrieved 2026-10-26)
- Completion: 2025-12-02 (actual) (ClinicalTrials.gov record NCT06139328, source copy `cardio:ctgov-nct06139328-2026-07-27`, retrieved 2026-10-26)
- Countries: Australia; Canada; Czechia; Germany; Hungary; Italy; New Zealand; Poland; Singapore; Slovakia; South Korea; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06139328, source copy `cardio:ctgov-nct06139328-2026-07-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06139328-2026-07-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
- Acronym: IRI-EXPLORE
- Condition: Myocardial Infarction
- Intervention (Drug): BI 765845
- Intervention (Drug): Placebo matching BI 765845
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 20bcd4b4f021d666768d7d5bf00399cb271d4e3a7bcf95d2d42b7594cbaab590
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
